Article Text

other Versions

PDF
One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare
  1. In-Ho Song1,
  2. Frank Heldmann2,
  3. Martin Rudwaleit1,3,
  4. Joachim Listing4,
  5. Heiner Appel1,
  6. Iris Haug-Rost5,
  7. Jürgen Braun2,
  8. Joachim Sieper1
  1. 1Department of Medical Clinic I/Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
  2. 2Department of Rheumatology, Centre of Rheumatology, Herne, Germany
  3. 3Endokrinologikum, Berlin, Germany
  4. 4Department of Statistics, German Rheumatism Research Center, Berlin, Germany
  5. 5Department of Rheumatology, Specialty Care/Medical Affairs Roche Pharma AG, Grenzach-Wyhlen, Germany
  1. Correspondence to Professor Joachim Sieper, Department of Medical Clinical I/Rheumatology, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin 12200, Germany; joachim.sieper{at}charite.de

Statistics from Altmetric.com

Recently we reported on a good clinical response at week 24, especially in tumour necrosis factor (TNF)-blocker-naive patients with ankylosing spondylitis (AS) who were treated with a first course of rituximab (two infusions of each 1000 mg of rituximab with 100 mg methylprednisolone at baseline and week 2).1

Here we report on the follow-up of these patients with a special focus on the good responders.

At week 24, patients regarded as responders were offered to be followed up and to receive a second course of rituximab in case of flare. A response was defined as reaching 20% improvement in disease activity according to the Assessment of SpondyloArthritis international Society criteria (ASAS20)2 compared with screening on at least two consecutive visits (out of four visits: week 12, week 16, week 20 and week 24). Flare was defined as a 1.5-point worsening of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) compared to the lowest BASDAI between week 12 and week 24. Flare patients were then followed for another 48 weeks (between the flare visit (=R-baseline) and R-week …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.